Victory Capital Management Inc. Reduces Stake in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Victory Capital Management Inc. reduced its position in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 14.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,112 shares of the medical instruments supplier’s stock after selling 1,023 shares during the period. Victory Capital Management Inc. owned about 0.11% of Mesa Laboratories worth $785,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Point72 Hong Kong Ltd purchased a new position in Mesa Laboratories during the first quarter worth $27,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new position in Mesa Laboratories during the second quarter worth $41,000. Tower Research Capital LLC TRC increased its position in Mesa Laboratories by 235.2% during the first quarter. Tower Research Capital LLC TRC now owns 295 shares of the medical instruments supplier’s stock worth $52,000 after buying an additional 207 shares in the last quarter. Global Retirement Partners LLC increased its position in Mesa Laboratories by 29.8% during the first quarter. Global Retirement Partners LLC now owns 414 shares of the medical instruments supplier’s stock worth $70,000 after buying an additional 95 shares in the last quarter. Finally, Amundi purchased a new position in Mesa Laboratories during the fourth quarter worth $102,000. Hedge funds and other institutional investors own 91.06% of the company’s stock.

Mesa Laboratories Price Performance

MLAB stock opened at $89.06 on Thursday. Mesa Laboratories, Inc. has a 52-week low of $87.77 and a 52-week high of $206.36. The stock’s fifty day simple moving average is $113.38 and its 200-day simple moving average is $131.33. The company has a quick ratio of 2.03, a current ratio of 2.93 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $479.50 million, a price-to-earnings ratio of 269.88 and a beta of 0.79.

Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported $1.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.09. Mesa Laboratories had a return on equity of 9.36% and a net margin of 0.83%. The business had revenue of $50.65 million for the quarter, compared to analysts’ expectations of $51.85 million. Equities research analysts expect that Mesa Laboratories, Inc. will post 5.46 EPS for the current year.

Mesa Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Thursday, November 30th will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.72%. The ex-dividend date of this dividend is Wednesday, November 29th. Mesa Laboratories’s payout ratio is currently 193.94%.

Insider Activity at Mesa Laboratories

In related news, Director John Bradley Schmieder sold 3,000 shares of Mesa Laboratories stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $123.32, for a total value of $369,960.00. Following the transaction, the director now owns 66,760 shares in the company, valued at $8,232,843.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Mesa Laboratories news, Director John Bradley Schmieder sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $123.32, for a total value of $369,960.00. Following the transaction, the director now directly owns 66,760 shares of the company’s stock, valued at $8,232,843.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Gary M. Owens sold 2,000 shares of the firm’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $142.82, for a total value of $285,640.00. Following the completion of the transaction, the chief executive officer now directly owns 30,032 shares in the company, valued at $4,289,170.24. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,000 shares of company stock worth $779,340. 5.20% of the stock is owned by insiders.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Mesa Laboratories in a research report on Thursday, October 5th. They set a “hold” rating for the company.

Mesa Laboratories Profile

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.